



CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia Online Edition https://www.imgge.bg.ac.rs/lat/o-nama/kapacitet-i-oprema/istrazivackadelatnost

https://indico.bio.bg.ac.rs/e/CoMBoS2

IMPRESSUM

PUBLISHER: Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade

FOR THE PUBLISHER: Dr. Sonja **Pavlović**

EDITOR: Dr. Zorana **Dobrijević**

EDITORIAL REVIEW BOARD: Prof. Dr. Silvana **Andrić** Dr. Valentina **Ćirković** Dr. Ivica **Dimkić** Prof. Dr. Branko **Jovčić** Prof. Dr. Gordana **Matić** Ass. Prof. Dr. Milena **Milutinović** Dr. Aleksandra **Stanković** Dr. Nemanja **Stanisavljević** Dr. Maja **Stoiljković**

EDITOR IN CHIEF: Prof. Dr. Dušanka **Savić-Pavićević**

DESIGN: Ivan **Strahinić**

All rights reserved Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade Belgrade, 2023 ISBN 978-86-7078-173-3

 \circledcirc Copyright 2023 by Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade <code>belgrade + 2023</code>

CoMBoS2

Content

Welcome speech 4

Congress Orginizers 5

MolBioS Award Winner 9

Plenary speakers 10

Session plenary speakers

- MOLECULAR BIOMEDICINE 11
- MOLECULAR BIOTECHNOLOGY 13
- MOLECULAR MECHANISMS OF CELL FUNCTIONS 16

Abstracts

Session PLENARY LECTURES 20

Session MOLECULAR BIOMEDICINE 25
PLENARY LECTURES 26
INVITED LECTURES 31
POSTERS 38

Session MOLECULAR BIOTECHNOLOGY 100 PLENARY LECTURES 101 INVITED LECTURES 107 POSTERS 112


Session MOLECULAR MECHANISMS OF CELL FUNCTIONS 126
PLENARY LECTURES 127
INVITED LECTURES 134
POSTERS 139

MolBioS Student Session 157

Project Corner 182

Congress Friends 190

Sponsors 191



<u>Nataša Tošić</u>,¹ Milena Ugrin,¹ Vojin Vuković,² Irena Marjanović,¹ Tatjana Kostić,¹ Darko Antić,^{2,3} Sanja Stanković,^{4,5} Vladimir Otašević,² Kristina Tomić,² Sofija Šarac,² Biljana Mihaljević,^{2,3} Sonja Pavlović,¹ Teodora Karan-Đurašević¹

¹Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia; ²Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia; ³School of Medicine, University of Belgrade, Belgrade, Serbia; ⁴Center for Medical Biochemistry, Clinical Center of Serbia, Belgrade, Serbia; ⁵Department of Biochemistry, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

Introduction: The long non-coding RNA (IncRNA) MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) dysregulated expression has been reported in a variety of cancers, but has been poorly investigated in chronic lymphocytic leukemia (CLL). The aim of this study was to investigate the expression pattern of IncRNA MALAT1 in CLL, and evaluate its prognostic significance.

Methods: MALAT1 expression was analyzed in peripheral blood mononuclear cells of 114 newly-diagnosed CLL patients and 20 healthy controls by qRT-PCR, and association with clinical and biological features at diagnosis was assessed.

Results: MALAT1 was overexpressed in CLL compared to control samples (p<0.001). MALAT1 expression was higher in male patients (p=0.003). It showed no correlation with age, leukocyte, lymphocyte and platelet count, and serum β 2-microglobulin, but exerted a positive correlation with hemoglobin level (r=0.315, p=0.003) and a negative correlation with lactate dehydrogenase level (r=-0.303, p=0.004). MALAT1 expression was higher in Binet A and B patients vs. Binet C patients (p=0.037). There was also a trend toward higher MALAT1 expression in patients with favorable (del13q) and intermediate (normal karyotype, trisomy12) cytogenetics in comparison to patients with unfavorable (del11q and del17p) cytogenetics (p=0.059). In addition, high MALAT1 levels were associated with CD38-negative status (p=0.017), but not with *IGHV* mutational status. While there was no association with the time to first treatment, longer median overall survival in MALAT1 high- vs. MALAT1 low-expressing cases was observed (142 vs. 82 months, log rank p=0.032).

Conclusion: LncRNA MALAT1 is up-regulated in CLL. High MALAT1 expression at diagnosis may be associated with better prognosis.

Key words: MALAT1; long non-coding RNA; expression; chronic lymphocytic leukemia; prognosis

Acknowledgements: This work was supported by grant No. 451-03-47/2023-01/200042 Ministry of Education, Science and Technological Development, Republic of Serbia.

